脊索瘤

预约门诊

生存率

癌症生存率或生存统计数据可以说明所涉癌症的患者在一段具体时间（例如 5 年或 10 年）内的生存百分比。这些数字可以帮助您和医护团队了解癌症治愈的概率（称为预后），并确定治疗计划。

癌症生存率通常基于一种具体癌症的众多患者收集研究数据而得出。由于患有脊索瘤的人很少，因此生存率可能不是很准确。

另外需要注意，生存统计数据需要 5 年或 10 年才能收集完毕。最新的生存率数据包括至少 5 年或 10 年前接受脊索瘤治疗的患者。这些患者没有机会获得最新的治疗。

考虑到这些因素，统计数据表明，脊索瘤患者确诊后的平均生存期约为 10 年。这意味着脊索瘤确诊患者中，大约一半人的生存期不到 10 年，一半人的生存期高于 10 年。

随着现代积极手术和更新治疗方法的出现，脊索瘤的生存率可能正在提高。医务人员或许能根据您的癌症分期和其他个人因素，为您提供更具体的生存统计数据。

影响生存率的因素

影响脊索瘤生存率的大多数因素是您无法控制的。例如：

  • 可以切除多少肿瘤。 这是预测脊索瘤结局的最重要的指标。如果能将肿瘤（包括一些周围的健康组织）完整切除，治愈的概率最大。
  • 肿瘤类型。 传统型和软骨样脊索瘤的预后优于低分化型和分化型脊索瘤。
  • 癌症是否复发或扩散。 如果脊索瘤在初次治疗后复发或转移，则预后较差。

在您最初从治疗中恢复后，尝试选择健康的生活方式以帮助保持整体健康。如果可能，尝试运动、均衡饮食、保持健康体重、保证充足睡眠、减轻压力、戒烟并限制饮酒量。这些有助于提高您的生活质量。

申请预约
分期医生与科室
Oct. 17, 2025

Living with 脊索瘤?

Connect with others like you for support and answers to your questions in the Sarcoma support group on Mayo Clinic Connect, a patient community.

Sarcoma Discussions

Colleen Young, Connect Director
Diagnosed with sarcoma? Let's share

1023 Replies Tue, Jan 13, 2026

westerncanuck
Uterine leiomyosarcoma with lung metastasis: Treatment options?

31 Replies Mon, Jan 12, 2026

See more discussions
  1. Elsevier Point of Care. Clinical Overview: Rare central nervous system tumors. https://www.clinicalkey.com. Accessed Nov. 20, 2024.
  2. Bone cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418. Accessed Aug. 21, 2025.
  3. Winn HR, ed. Youmans and Winn Neurological Surgery. 8th ed. Elsevier; 2023. https://www.clinicalkey.com. Accessed Nov. 20, 2024.
  4. Zenonos GA. Chordoma of the skull base. https://www.uptodate.com/contents/search. Accessed Aug. 21, 2025.
  5. Chordoma. National Cancer Institute. https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-bone-tumors/chordoma. Accessed Aug. 21, 2025.
  6. Barber SM, et al. Chordoma — Current understanding and modern treatment paradigms. Journal of Clinical Medicine. 2021; doi:10.3390/jcm10051054.
  7. Banks C, et al. ICAR: Endoscopic skull-base surgery. International Forum of Allergy & Rhinology. 2019; doi:10.1002/alr.22326.
  8. Stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). RadiologyInfo.org. https://www.radiologyinfo.org/en/info/stereotactic. Accessed Jan. 29, 2025.
  9. Dickerson TE, et al. Recurrent metastatic chordoma to the liver: A case report and review of the literature. Current Oncology. 2022; doi:10.3390/curroncol29070367.
  10. Song PH, et al. Symptom burden and life challenges reported by adult chordoma patients and their caregivers. Quality of Life Research. 2017; doi:10.1007/s11136-017-1544-2.
  11. Young VA, et al. Clinical study: Characteristics and patterns of metastatic disease from chordoma. Sarcoma. 2015; doi:10.1155/2015/517657.
  12. Alshammari J, et al. Clival chordoma with an atypical presentation: A case report. Journal of Medical Case Reports. 2012; doi:10.1186/1752-1947-6-410.
  13. Dudhe S, et al. Challenging the giant: A case report on a huge sacrococcygeal chordoma and its radiological insights. Radiology Case Reports. 2025; doi:10.1016/j.radcr.2024.10.157.
  14. Zhou Y, et al. The clinical outcomes for chordomas in the cranial base and spine: A single center experience. Medicine. 2019; doi:10.1097/MD.0000000000015980.
  15. Medical oncologic treatment of spinal malignancies and outcomes. Video. Mayo Clinic; 2023.
  16. Murphey MD, et al. Imaging of spinal chordoma and benign notochordal cell tumor (BNCT) with radiologic pathologic correlation. Skeletal Radiology. 2023; doi:10.1007/s00256-022-04158-7.
  17. Baig Mirza A, et al. Surgical management of spinal chordoma: A systematic review and single-center experience. World Neurosurgery. 2021; doi:10.1016/j.wneu.2021.09.001.
  18. Court C, et al. Management of chordoma of the sacrum and mobile spine. Orthopaedics & Traumatology: Surgery & Research. 2022; doi:10.1016/j.otsr.2021.103169.
  19. Goumenos S, et al. Clinical outcome after surgical treatment of sacral chordomas: A single-center retrospective cohort of 27 patients. Cancers. 2024; doi:10.3390/cancers16050973.
  20. Garofalo F, et al. The unresolved case of sacral chordoma: From misdiagnosis to challenging surgery and medical therapy resistance. Annals of Coloproctology. 2014; doi:10.3393/ac.2014.30.3.122.
  21. Zhang J, et al. Intradural cervical chordoma with diffuse spinal leptomeningeal spread: Case report and review of the literature. European Spine Journal. 2018; doi:10.1007/s00586-017-5443-6.
  22. Passeri T, et al. The mutational landscape of skull base and spinal chordomas and the identification of potential prognostic and theranostic biomarkers. Journal of Neurosurgery. 2023; doi:10.3171/2023.1.JNS222180.
  23. Ma T, et al. Current understanding of brachyury in chordoma. BBA — Reviews on Cancer. 2023; doi:10.1016/j.bbcan.2023.189010.
  24. Elsamadicy AA, et al. The association of gender in the management and prognosis of vertebral and sacral chordoma: A SEER analysis. Journal of Clinical Medicine. 2025; doi:10.3390/jcm14051737.
  25. What is cancer? American Cancer Society. https://www.cancer.org/cancer/understanding-cancer/what-is-cancer.html. Accessed Aug. 31, 2025.
  26. Soule E, et al. Current management and image review of skull base chordoma: What the radiologist needs to know. 2021; doi:10.25259/JCIS_139_2021.
  27. CT scan. Mayo Clinic. https://www.mayoclinic.org/tests-procedures/ct-scan/about/pac-20393675. Accessed Sept. 4, 2025.
  28. American College of Surgeons. Bone cancer. In: AJCC Cancer Staging System. American College of Surgeons; 2025. https://online.statref.com. Accessed Sept. 8, 2025.
  29. Dastgheyb SS, et al. A prospective phase I/II clinical trial of high-dose proton therapy for chordomas and chondrosarcomas. Advances in Radiation Oncology. 2024; doi:10.1016/j.adro.2024.101456.
  30. Childhood chordoma treatment (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/bone/hp/child-chordoma-treatment-pdq. Accessed Sept. 9, 2025.
  31. Immunotherapy. American Cancer Society. https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html. Accessed Sept. 18, 2025.
  32. Shyam Sunder S, et al. Adverse effects of tyrosine kinase inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management. Signal Transduction and Targeted Therapy. 2023; doi:10.1038/s41392-023-01469-6.
  33. Cancer survival rate: What it means for your prognosis. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer/art-20044517. Accessed Sept. 18, 2025.
  34. Cancer survivors: Care for your body after treatment. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer-survivor/art-20044015. Accessed Sept. 18, 2025.
  35. Stacchioti S, et al. Best practices for the management of local-regional recurrent chordoma: A position paper by the Chordoma Global Consensus Group. Annals of Oncology. 2017; doi:10.1093/annonc/mdx05.
  36. Bone cancer. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/bone-cancer/symptoms-causes/syc-20350217. Accessed Sept. 11, 2025.
  37. Steffner RJ, et al. Staging of bone and soft-tissue sarcomas. Journal of the American Academy of Orthopedic Surgeons. 2018; doi:10.5435/JAAOS-D-17-00055.
  38. Terminal cancer. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/terminal-cancer. Accessed Sept 12, 2025.
  39. Cancer pain: Relief is possible. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer-pain/art-20045118. Accessed Sept. 18, 2025.
  40. Health Education & Content Services. Chordoma overview. Mayo Clinic; 2025.
  41. Sahgal A, et al. Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: Preliminary outcomes. Neuro-Oncology. 2015; doi:10.1093/neuonc/nou347.
  42. Chhabra AM, et al. Proton therapy for spinal tumors: A consensus statement from the Particle Therapy Cooperative Group. International Journal of Radiation Oncology, Biology, Physics. 2024; doi:10.1016/j.ijrobp.2024.04.007.
  43. Maroufi SF, et al. Stereotactic radiosurgery in the management of skull base chordomas: A comprehensive systematic review and meta-analysis. Neurosurgical Focus. 2024; doi:10.3171/2024.2.FOCUS249.
  44. Ghaith, AK, et al. Impact of proton versus photon radiotherapy on overall survival in the management of spinal chordoma and mortality risk prediction: A nationwide analysis. Journal of Neuro-Oncology. 2025; doi:10.1007/s11060-025-05104-y.
  45. Myneni, S, et al. Exploring perspectives on skull base chordoma management: A modified Delphi approach to consensus. Journal of Neuro-Oncology. 2025; doi:10.1007/s11060-025-05088-9.
  46. Han Y, et al. Clinical differences among histological categories of sarcoma: Insights from 97,062 patients. Cancers (Basel). 2025; doi:10.3390/cancers17101706.
  47. Rodrigues ACLF, et al. Proton beam and carbon ion radiotherapy in skull base chordoma: A systematic review, meta-analysis and meta-regression with trial sequential analysis. Neurosurgical Review. 2024; doi:10.1007/s10143-024-03117-1.

相关

相关医疗程序

产品与服务

脊索瘤

CON-20248515